Primary Site >> Biliary tract Cancer

Gene >> PIK3CA

  • 2008
  • 2009
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
PMID: 18181165
 Ref: Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
PMID: 19440799
 Ref: KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
PMID: 21051183
Ref: Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
PMID: 21303542
Ref: Genetics of hepatobiliary carcinogenesis.
PMID: 21538283
 Ref: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
PMID: 22180306
 Ref: Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
PMID: 23391413
Ref: Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
PMID: 23832540
 Ref: High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.
PMID: 24186137
Ref: Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.
PMID: 24186143
Ref: Molecular characterization of gallbladder cancer using somatic mutation profiling.
PMID: 24508317
Ref: New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
PMID: 24563076
Ref: Mutation profiling in gallbladder cancer in Indian population.
PMID: 24739824
Ref: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
PMID: 24889489
 Ref: Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer.
PMID: 25749176
Ref: Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases.
PMID: 26111977
Ref: PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
PMID: 26498688
 Ref: Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
PMID: 26717940
Ref: Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
PMID: 26857926
Ref: EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma.
PMID: 27020207
Ref: Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing.
PMID: 27267833
Ref: The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
PMID: 27317099
Ref: Molecular characteristics of biliary tract cancer.
PMID: 27823638
Ref: KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers.
PMID: 28008299
 Ref: Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.
PMID: 28029662
Ref: K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
PMID: 28544747
Ref: Genetic alterations in Japanese extrahepatic biliary tract cancer.
PMID: 28693246
Ref: Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation.
PMID: 28694672
Ref: Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components.
PMID: 28698100
Ref: Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients.
PMID: 28900470
Ref: Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
PMID: 29024814
 Ref: Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
PMID: 29224898
Ref: Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
PMID: 29348486
Ref: Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.
PMID: 29416916
Ref: Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.
PMID: 29527009
Ref: Investigation of targetable predictive and prognostic markers in gallbladder carcinoma.
PMID: 29564177
Ref: New developments in systemic therapy for advanced biliary tract cancer.
PMID: 29893894